(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 April 2007 (05.04.2007)

PCT

(10) International Publication Number
WO 2007/038115 A3

(51) International Patent Classification:
A61K 31/4439 (2006.01) *A61P 25/28* (2006.01)
A61K 31/445 (2006.01)

(21) International Application Number:
PCT/US2006/036603

(22) International Filing Date:
20 September 2006 (20.09.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/719,353 22 September 2005 (22.09.2005) US
60/727,377 17 October 2005 (17.10.2005) US

(71) Applicant *(for all designated States except US)*: **SB PHARMCO PUERTO RICO INC.**; The Prentice Hall Corp. System, c/o FGR Corporate Services, Inc., BBV Tower, 8th Floor, 254 Munoz Rivera Avenue, San Juan, 00918 (PR).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ROSES, Allen, D.** [US/US]; GlaxoSmithKline, Five Moore Drive, P.O. Box 13398, Durnorth Carolina, 27709 (US). **SAUNDERS, Ann, M.** [US/US]; GlaxoSmithKline, Five Moore Drive, P.O. Box 13398, Durnorth Carolina, 27709 (US).

(74) Agents: **SIEBURTH, Kathryn, L.** et al.; Glaxosmtihkline, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
— *of inventorship (Rule 4.17(iv))*


Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
13 December 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PPAR-GAMMA AGONISTS FOR IMPROVEMENT OF COGNITIVE FUNCTION IN APOE4 NEGATIVE PATIENTS





(57) Abstract: A method for improving cognitive function in a subject suffering from or susceptible to MCI, Alzheimer's disease or other dementias, which subject is not homozygous for the APOE4 allele, comprising the steps of: (i) screening the subject to determine that the subject is not homozygous for the APOE4 allele; and then (ii) administering a safe and effective amount of a PPAR-gamma agonist to said subject.

WO 2007/038115 A3